Catalog No.
DHD23001
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
Interferon alpha/beta receptor 1, Cytokine receptor family 2 member 1, Cytokine receptor class-II member 1, CRF2-1, IFN-R-1, IFNAR1, IFNAR, IFN-alpha/beta receptor 1, Type I interferon receptor 1
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P17181
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
MDX-1333, MEDI-546, CAS: 1326232-46-5
Clone ID
Anifrolumab
Trial of Anifrolumab in Active Systemic Lupus Erythematosus, PMID: 31851795
Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus, PMID: 28130918
Anifrolumab, PMID: 32310439
Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials, PMID: 32814461
Anifrolumab in systemic lupus erythematosus: current knowledge and future considerations, PMID: 32237942
Anifrolumab in Systemic Lupus Erythematosus, PMID: 32320576
Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date, PMID: 31190735
Anifrolumab in Systemic Lupus Erythematosus. Reply, PMID: 32320577
Antibodies to watch in 2020, PMID: 31847708
Long-Term Safety and Efficacy of Anifrolumab in Adults With Systemic Lupus Erythematosus: Results of a Phase II Open-Label Extension Study, PMID: 33225631
[Anifrolumab in systemic lupus erythematosus], PMID: 29411096
Anifrolumab for the treatment of active systemic lupus erythematosus: a meta-analysis of randomized controlled trials, PMID: 33216191
State-of-the-art treatment of systemic lupus erythematosus, PMID: 32134201
Positive results for anifrolumab in phase III SLE trial, PMID: 32020079
Anifrolumab, PMID: 34406725
Cutaneous Lupus Erythematosus: Progress and Challenges, PMID: 32248318
Safety and tolerability of anifrolumab, a monoclonal antibody targeting type I interferon receptor, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study, PMID: 30793642
Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus, PMID: 29644082
Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus, PMID: 30588322
Efficacy of anifrolumab in systemic lupus erythematosus: a critical analysis of the TULIP trials, PMID: 32493153
Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers, PMID: 29644080
Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE, PMID: 30538817
Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?, PMID: 28765121
Systemic lupus erythematosus, PMID: 29224671
Kidney outcomes for children with lupus nephritis, PMID: 32725543
Treatment of cutaneous lupus erythematosus: current approaches and future strategies, PMID: 32141953
Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-α receptor 1 antibody, PMID: 25606664
Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis, PMID: 33002950
Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus, PMID: 33977796
B Cell Therapy in Systemic Lupus Erythematosus: From Rationale to Clinical Practice, PMID: 32754605
FDA approves AstraZeneca's anifrolumab for lupus, PMID: 34363027
Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab, PMID: 29420200
Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials, PMID: 33597205
Microglia-dependent synapse loss in type I interferon-mediated lupus, PMID: 28614301
Modulation of Cardiometabolic Disease Markers by Type I Interferon Inhibition in Systemic Lupus Erythematosus, PMID: 32909675
Type I interferon gene signature test-low and -high patients with systemic lupus erythematosus have distinct gene expression signatures, PMID: 31660791
Suppression of T Cell Activation and Collagen Accumulation by an Anti-IFNAR1 mAb, Anifrolumab, in Adult Patients with Systemic Sclerosis, PMID: 25993119
Comment on: 'Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab' by Eric Morand et al, PMID: 30373882
Targeted Biologic Therapy for Systemic Lupus Erythematosus: Emerging Pathways and Drug Pipeline, PMID: 32002918
Response to: 'Comment on: 'Lupus Low Disease Activity State(LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hocanalysis of the Phase IIb MUSE trial of anifrolumab' by Eric Morand et al' by Isenberg, PMID: 30373881
Correction: Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE, PMID: 30613421
A Tale of Two Trials, PMID: 32182394
Anti-IFNαR Mabs for the treatment of systemic lupus erythematosus, PMID: 33085537
String of successful trials in SLE: have we cracked the code?, PMID: 32095250
Exposure-Response Analysis for Selection of Optimal Dosage Regimen of Anifrolumab in Patients With Systemic Lupus Erythematosus, PMID: 33629110
[Biologicals and small molecules for systemic lupus erythematosus], PMID: 32206866
Targeting interferons as a strategy for systemic sclerosis treatment, PMID: 29106987
Type I interferon antagonists in clinical development for lupus, PMID: 32700979
Interferon-targeted therapy in systemic lupus erythematosus: Is this an alternative to targeting B and T cells?, PMID: 27497254
A Successful Trial for Lupus - How Good Is Good Enough?, PMID: 31851796
For research use only. Not for human or drug use.
